Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2018 | Targeting TGF-β signaling in cancer

Carl-Henrik Heldin • 15 Nov 2018
NCRI 2018
General

As a result of its opposing tumor promoting and suppressive abilities, transforming growth factor beta (TGF-β) and its pathways have provided potential opportunities for drug development. Carl-Henrik Heldin, PhD, from the Ludwig Institute for Cancer Research, Uppsala, Sweden, presents an exciting approach to inhibiting several stages of tumor progression via this molecule, which are being investigated in trials. Prof. Hendrick speaks at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK, on the state-of-the-art, novel data that contribute to our increasing knowledge of the role of TGF-β signaling in the development of cancer.

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals